Shanghai Righton Yuntai Biomedical Technology Co., Ltd announced that it will receive CNY 40 million in an equity round of funding on April 6, 2023. The transaction will include participation from existing investor, Shanghai Rightongene Biotechnology Co., Ltd. to retain 100% stake in the company. The transaction has been approved in the 14th meeting of the second board of directors of the company, and it still needs to be submitted to the general meeting of shareholders for deliberation.

After the completion of capital increase, the registered capital of the company will increase to CNY 50 million.